ConductScience.org, home

Paper37597580

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

González-Martín A and 11 others. Ann Oncol, 2023. Cited by 372 papers, by iCite.

Cite this record

ConductScience Library. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Papers, record 37597580. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37597580

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
PubMed
Journal
Ann Oncol
PubMed
Year
2023
PubMed
Publication types
Practice Guideline, Journal Article
PubMed
Citations, by iCite
372
iCite
Relative citation ratio, by iCite
39.1
iCite
Revised in PubMed
2026-03-10
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1González-Martín AA
2Harter PP
3Leary AA
4Lorusso DD
5Miller RER E
6Pothuri BB
7Ray-Coquard II
8Tan DSPD S P
9Bellet EE
10Oaknin AA
11Ledermann JAJ A
12ESMO Guidelines Committee. Electronic address: [email removed]Group

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06827353Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination DeficiencyBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by247

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 372 citations.

PMIDTitleJournalYearIn PapersSource
42968661Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS-STING-STAT3 survival axis.Clin Transl Med2026https://conductscience.org/library/papers/42968661PubMed
42967589Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer.Clin Transl Med2026https://conductscience.org/library/papers/42967589PubMed
42947969Spatial lipidomics in gynecologic malignancies: molecular identification, cellular attribution, and mechanistic validation.Front Mol Biosci2026https://conductscience.org/library/papers/42947969PubMed
42942783Bench-to-Bedside Development of IMNN-001: A Non-Viral IL-12 Gene Therapy for Advanced Ovarian Cancer.Pharmaceutics2026https://conductscience.org/library/papers/42942783PubMed
42934810Metabolic targeting of cyst(e)ine enhances carboplatin responsiveness in ovarian cancer.Cancer Metab2026https://conductscience.org/library/papers/42934810PubMed
42930189A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.Curr Oncol2026https://conductscience.org/library/papers/42930189PubMed
42923094Epigenetic adaptations and vulnerabilities in ovarian cancer drug-tolerant persister cells.NAR Cancer2026https://conductscience.org/library/papers/42923094PubMed
42919395Decoding the endothelin-1 network: molecular drivers of ovarian cancer malignancy and new therapeutic horizons.J Ovarian Res2026https://conductscience.org/library/papers/42919395PubMed
42894212ACSF2 Functions as a regulatory switch for PARP inhibitor sensitivity in platinum-sensitive and homologous recombination-proficient high-grade serous ovarian cancer.Cancer Cell Int2026https://conductscience.org/library/papers/42894212PubMed
42891008Using machine learning to estimate time-to-progression in ovarian cancer based on cancer registry and administrative health data.ESMO Real World Data Digit Oncol2026https://conductscience.org/library/papers/42891008PubMed
42881479Molecular Landscapes of Tumor Dormancy in Gynecologic Malignancies: From Survival Mechanisms to Precision Interception.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42881479PubMed
42870294Carboxylesterase 1 is a core metabolic vulnerability of platinum-resistant high-grade serous ovarian carcinoma.J Exp Clin Cancer Res2026https://conductscience.org/library/papers/42870294PubMed
42836989DCE-MRI histogram analysis for predicting survival in patients with epithelial ovarian carcinoma.Abdom Radiol (NY)2026https://conductscience.org/library/papers/42836989PubMed
42830865Real-world outcomes in patients with advanced epithelial ovarian cancer receiving niraparib as first-line maintenance: a European retrospective cohort study.ESMO Real World Data Digit Oncol2026https://conductscience.org/library/papers/42830865PubMed
42811314Bridging the gap between guidelines and practice: genetic counseling uptake and barriers in patients with ovarian malignancies.BMC Womens Health2026https://conductscience.org/library/papers/42811314PubMed
42796295Chemotherapy Response Score and Survival Outcomes After Neoadjuvant Chemotherapy in High-Grade Serous Tubo-Ovarian Carcinoma: A Multicenter Retrospective Study.Medicina (Kaunas)2026https://conductscience.org/library/papers/42796295PubMed
42793800Pregnancy Deciduosis Mimicking Abdominal Tuberculosis and Peritoneal Carcinomatosis: A Case Report.Diagnostics (Basel)2026https://conductscience.org/library/papers/42793800PubMed
42782897Clinical Value of an LDH-CA125-NLR Panel for Diagnosis, Platinum Resistance, and Prognostic Assessment in Epithelial Ovarian Cancer.Curr Oncol2026https://conductscience.org/library/papers/42782897PubMed
42774967Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience.Gynecol Oncol Rep2026https://conductscience.org/library/papers/42774967PubMed
42755018PD-L1 in Ovarian Cancer: Immune Evasion, Tumor-Intrinsic Signaling, and Chemoresistance.Cancer Med2026https://conductscience.org/library/papers/42755018PubMed

See all 247 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37597580

GET https://conductscience.org/api/papers/v1/37597580/cited_by?page=2